APA

Tong G., Wang J., Sverdlov O., Huang S., Slemmon R., Croop R., Castaneda L., Gu H., Wong O., Li H., Berman R. M., Smith C., Albright C. F. & Dockens R. C. (20120716). Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. : Clinical therapeutics.

Chicago

Tong Gary, Wang Jun-Sheng, Sverdlov Oleksandr, Huang Shu-Pang, Slemmon Randy, Croop Robert, Castaneda Lorna, Gu Huidong, Wong Oi, Li Hewei, Berman Robert M, Smith Christina, Albright Charles F and Dockens Randy C. 20120716. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. : Clinical therapeutics.

Harvard

Tong G., Wang J., Sverdlov O., Huang S., Slemmon R., Croop R., Castaneda L., Gu H., Wong O., Li H., Berman R. M., Smith C., Albright C. F. and Dockens R. C. (20120716). Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. : Clinical therapeutics.

MLA

Tong Gary, Wang Jun-Sheng, Sverdlov Oleksandr, Huang Shu-Pang, Slemmon Randy, Croop Robert, Castaneda Lorna, Gu Huidong, Wong Oi, Li Hewei, Berman Robert M, Smith Christina, Albright Charles F and Dockens Randy C. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. : Clinical therapeutics. 20120716.